ENANTA PHARMACEUTICALS, INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
ENANTA PHARMACEUTICALS, INC (ENTA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 401.28 thousand shares for the 3-month period ending 2015-12-31, per its 10-Q filed 2016-02-09.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2016-02-09
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2015-12-31 was 401.28K shares, a 29.01% increase year-over-year.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2015-09-30 was 13.40K shares, a 168.00% increase year-over-year.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2015-06-30 was 104.90K shares, a 8.79% increase year-over-year.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2015-03-31 was 97.40K shares, a 19.39% increase year-over-year.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2015 was 526.75K shares, a 7.82% increase from fiscal 2014.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2014 was 488.57K shares, a 34.11% increase from fiscal 2013.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2013 was 364.32K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|
| 2015-12-31 | 401.28K shares 10-Q · filed 2016-02-09 | 414.68K shares derived: sum of 2 quarters · filed 2016-02-09 | 519.58K shares derived: sum of 3 quarters · filed 2016-02-09 | 616.98K shares derived: sum of 4 quarters · filed 2016-02-09 |
| 2015-09-30 | 13.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-11 | 118.30K shares derived: sum of 2 quarters · filed 2015-12-11 | 215.70K shares derived: sum of 3 quarters · filed 2015-12-11 | 526.75K shares 10-K · filed 2015-12-11 |
| 2015-06-30 | 104.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-08-10 | 202.30K shares derived: sum of 2 quarters · filed 2015-08-10 | 513.36K shares 10-Q · filed 2015-08-10 | 518.36K shares derived: sum of 4 quarters · filed 2015-08-10 |
| 2015-03-31 | 97.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-05-08 | 408.45K shares 10-Q · filed 2015-05-08 | 413.45K shares derived: sum of 3 quarters · filed 2015-05-08 | 509.88K shares derived: sum of 4 quarters · filed 2015-05-08 |
| 2014-12-31 | 311.06K shares 10-Q · filed 2015-02-06 | 316.06K shares derived: sum of 2 quarters · filed 2015-02-06 | 412.48K shares derived: sum of 3 quarters · filed 2015-02-06 | 494.06K shares derived: sum of 4 quarters · filed 2015-02-06 |
| 2014-09-30 | 5.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2014-12-11 | 101.42K shares derived: sum of 2 quarters · filed 2014-12-11 | 183.00K shares derived: sum of 3 quarters · filed 2014-12-11 | 488.57K shares 10-K · filed 2014-12-11 |
| 2014-06-30 | 96.42K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-08-12 | 178.00K shares derived: sum of 2 quarters · filed 2014-08-12 | 483.57K shares 10-Q · filed 2014-08-12 | 491.87K shares derived: sum of 4 quarters · filed 2014-08-12 |
| 2014-03-31 | 81.58K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-05-12 | 387.15K shares 10-Q · filed 2014-05-12 | 395.45K shares derived: sum of 3 quarters · filed 2014-05-12 | 400.79K shares derived: sum of 4 quarters · filed 2014-05-12 |
| 2013-12-31 | 305.57K shares 10-Q · filed 2014-02-13 | 313.87K shares derived: sum of 2 quarters · filed 2014-02-13 | 319.21K shares derived: sum of 3 quarters · filed 2014-02-13 | |
| 2013-09-30 | 8.30K shares derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-18 | 13.64K shares derived: sum of 2 quarters · filed 2013-12-18 | 364.32K shares 10-K · filed 2013-12-18 | |
| 2013-06-30 | 5.34K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-08-12 | 356.02K shares 10-Q · filed 2013-08-12 | ||
| 2013-03-31 | 350.68K shares 10-Q · filed 2013-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |